Phase 1 N=71 Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD: A Pilot Study
Obesity · GERD
Primary: Pantoprazole Apparent Oral Clearance — 0.42; 0.29; 0.23 L/hr/kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)
Gonococcal Infection
Primary: The Proportion of Participants That Become Infected With Individual N. Gonorrhoeae Strains in Non-competitive Infections — 0.80; 1.00 proportion of participants — p=1.000
Phase 1 N=15 Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons
HIV-1 Infection
Primary: Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE) — 0 percentage of participants
Phase 1 N=11 Glutamate Reducing Interventions in Schizophrenia
Clinical High Risk for Psychosis
Primary: Percent Change in Left Hippocampal CA1 Region Cerebral Blood Volume (CBV) From Baseline to Day 14 — 0.40684405; -0.081559; 0.0219668; -0.0269017 Percent change
Phase 1 N=22 NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
Tumors
Primary: Number of Subjects Reporting Adverse Events (AEs) and Dose-limiting Toxicities (DLTs) — 11; 11; 0; 0 Participants
Phase 1 N=40 Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
Ebola Virus
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-EBO S Vaccine Administration — 3; 3; 6; 16 Participants
Phase 1 N=451 Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
Advanced Cancer
Primary: Phase 1A: Number of Participants Experiencing Adverse Events (AEs) — 114 Participants
Phase 1 N=19 Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) of CPX-POM — 0; 0; 0; 0 participants
Phase 1 N=24 A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers
Migraine
Primary: Cmax — 11670; 9861; 11680; 3705 pg/mL
Phase 1 N=23 A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease
Health Volunteers, Huntington Disease
Primary: Sigma-1 Receptor Occupancy — 91.21; 87.19; 86.67; 77.96 percentage of receptor occupancy
Phase 1 N=15 A Study of LY900014 in Healthy Chinese Participants
Healthy
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Serum Concentration Versus Time Curve From Time Zero to 10 Hours Postdose (AUC[0-10h]) — 708; 1580; 1600 picomole *…
Phase 1 N=65 A Safety and Immunogenicity Trial of IHV01
HIV Infection
Primary: Number of Participants With Local and Systemic Reactogenicity Signs and Symptoms — 3; 8; 4; 5 Participants
Phase 1 N=32 To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects
SARS-CoV-2 Infection
Primary: Preliminary Safety and Tolerability of CT-P59 — 0; 2; 1; 0 Participants
Phase 1 N=18 Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)
Cytomegalovirus Infections
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event (AE) — 100.0; 83.3; 0.0; 33.3 Percentage of participants
Phase 1 N=58 Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
Allergic Bronchopulmonary Aspergillosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAE) — 0; 3; 2; 2 participants